Psychedelic: Compass Pathways reports six-month data for psilocybin drug

In this week's "Psychedelic," recurring series focused on psychedelic stock news, looks back on study results, drug delivery evaluation and last patient dosing. COMPASS PATHWAYS REPORTS SIX-MONTH DATA FROM COMP006 TRIAL: Compass Pathways (CMPS) announced Tuesday the 26-week results from its second ongoing Phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression which confirm COMP360's rapid onset and durable profile. The 26-week findings in nearly 600 patients build on previously reported results from the first Phase 3 trial, COMP005, which demonstrated rapid onset and durable response to at least 6 months, with a generally well-tolerated and safe profile in people living with TRD. In COMP006, participants had current depressive episodes lasting on average over three years and an average of more than six lifetime depressive episodes. Within the context of this severe population, 39% of participants in the 25 mg arm achieved a clinically meaningful reduction in Montgomery-Asberg Depression Rating Scale by week 6, following two fixed doses of COMP360, and maintained durable response at least through Week 26. This.